These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 22297008

  • 1. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
    Gardner-Roehnelt NM.
    Clin J Oncol Nurs; 2012 Feb; 16(1):56-64. PubMed ID: 22297008
    [Abstract] [Full Text] [Related]

  • 2. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H.
    Int J Mol Sci; 2019 Jun 22; 20(12):. PubMed ID: 31234481
    [Abstract] [Full Text] [Related]

  • 3. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
    Pokuri VK, Fong MK, Iyer R.
    Curr Oncol Rep; 2016 Jan 22; 18(1):7. PubMed ID: 26743514
    [Abstract] [Full Text] [Related]

  • 4. Antitumor effects of somatostatin analogs in neuroendocrine tumors.
    Sidéris L, Dubé P, Rinke A.
    Oncologist; 2012 Jan 22; 17(6):747-55. PubMed ID: 22628056
    [Abstract] [Full Text] [Related]

  • 5. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
    Ryan P, Phan AT, Adelman DT, Iwasaki M.
    Clin J Oncol Nurs; 2016 Dec 01; 20(6):E139-E146. PubMed ID: 27857269
    [Abstract] [Full Text] [Related]

  • 6. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA, Wolin EM, Liyanage N, Lowenthal SP, Mirakhur B, Pommier RF, Shaheen M, Vinik AI, ELECT Study Investigators.
    Endocr Pract; 2018 Mar 01; 24(3):243-255. PubMed ID: 29547049
    [Abstract] [Full Text] [Related]

  • 7. New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.
    Weber M.
    Clin Adv Hematol Oncol; 2014 Dec 01; 12(12 Suppl 19):12-7. PubMed ID: 25768104
    [No Abstract] [Full Text] [Related]

  • 8. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M, Strosberg J.
    Drugs; 2015 May 01; 75(8):847-58. PubMed ID: 25911185
    [Abstract] [Full Text] [Related]

  • 9. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF.
    Ann Oncol; 2000 Sep 01; 11(9):1127-30. PubMed ID: 11061606
    [Abstract] [Full Text] [Related]

  • 10. Commentary: Somatostatin analogs-How we choose, and why.
    Reidy-Lagunes D, Raj N, Saltz L.
    Semin Oncol; 2017 Apr 01; 44(2):157-158. PubMed ID: 28923214
    [No Abstract] [Full Text] [Related]

  • 11. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E, Deshpande HA, Stein SM.
    Drugs Today (Barc); 2018 Aug 01; 54(8):457-465. PubMed ID: 30209440
    [Abstract] [Full Text] [Related]

  • 12. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.
    Strosberg J, Kvols L.
    World J Gastroenterol; 2010 Jun 28; 16(24):2963-70. PubMed ID: 20572298
    [Abstract] [Full Text] [Related]

  • 13. Established clinical use of octreotide and lanreotide in oncology.
    Oberg K.
    Chemotherapy; 2001 Jun 28; 47 Suppl 2():40-53. PubMed ID: 11275701
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
    Oberg K.
    Ann Oncol; 2001 Jun 28; 12 Suppl 2():S111-4. PubMed ID: 11762335
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
    O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, Blumberg J, Ruszniewski P.
    Cancer; 2000 Feb 15; 88(4):770-6. PubMed ID: 10679645
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
    Massironi S, Conte D, Rossi RE.
    Scand J Gastroenterol; 2016 Feb 15; 51(5):513-23. PubMed ID: 26605828
    [Abstract] [Full Text] [Related]

  • 19. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
    Enzler T, Fojo T.
    Semin Oncol; 2017 Apr 15; 44(2):141-156. PubMed ID: 28923213
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.
    Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Välimäki MJ, Renstrup J, de Vries EG, Oberg KE.
    J Clin Oncol; 1999 Apr 15; 17(4):1111. PubMed ID: 10561168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.